At the Max Planck Institute of Molecular Physiology in Dortmund, Peng Wu's research group has designed a "molecular eraser" that works like a microscopic trap: it hunts down the genetic blueprint of a deadly cancer protein before that protein can even exist. This breakthrough challenges everything scientists thought they knew about how cancer drugs must work.
The stakes are enormous. The RAS protein, when mutated, causes roughly 40% of all colorectal cancers and more than 90% of pancreatic cancers—the deadliest of all malignancies. Yet for decades, RAS was considered "undruggable," too slippery for conventional pharmaceutical approaches to grip. Although the first RAS-targeting drug for lung cancer finally won approval in 2021, developing additional treatments has remained painfully complex and expensive. Wu's team is pursuing an entirely different strategy: rather than fighting the protein itself, stop it from being made in the first place.
The solution is elegant. The researchers created a specially designed chimeric molecule called a RIBOTAC that acts as a hunter-and-capture system. One end of the molecule binds tightly to the harmful NRAS mRNA—the genetic instruction manual that tells cells how to build the cancer protein. The other end of the RIBOTAC carries a chemical "hook" that snares RNA-degrading enzymes, cellular cleanup machinery that naturally breaks down RNA. Once hooked, these enzymes shred the bound mRNA, preventing the cancer protein from ever being assembled.
What happened next defied expectation. When Wu's team tested their RIBOTAC on cancer cells, it successfully degraded the target mRNA. But when they measured the total amount of NRAS protein in the cells afterward, they found almost no change. The researchers believe they had eliminated only a rare subform of the protein—less than 1% of the total amount—but the effects should have been negligible. Instead, something extraordinary occurred: the treated cancer cells transformed radically. Their shape shifted. Their behavior changed. The cells bore what Wu describes as a new "biological fingerprint" that matched no known class of drug.
This result upends a fundamental principle of drug research that has guided the field for generations. The underlying assumption has always been straightforward: a therapeutic effect requires significant disruption of your target—whether that means degrading large portions of a problematic RNA, inhibiting a protein, or activating a dormant one. But Wu's findings suggest otherwise. By erasing even a tiny fraction of one mRNA variant, his team triggered extensive cellular reorganization. The removal of less than 1% of the target RNA produced dramatic, measurable effects.
"The molecules left a biological fingerprint that does not match any known class of active substances," Wu explains. "This suggests that we are targeting entirely new signaling pathways or mechanisms."
What comes next is a race to understand why. Wu's team plans to decode exactly which cellular pathways the RIBOTAC influences and how that influence hammers cancer cells. Simultaneously, they will refine the chemistry and improve the molecule's binding strategy to engineer next-generation "molecular erasers" that work even more effectively. The published work, which appeared in JACS Au in 2026, may represent the opening of an entirely new chapter in cancer therapy—one where the smallest intervention can cascade into the biggest changes.